3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
10
Terminated
8
Withdrawn
5
Unknown
4
Recruiting
2
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Polycystic Ovary Syndrome
3
Leukoplakia, Oral
2
Insulin Resistance
2
Glioblastoma
2
Erythroplasia
2
Endometrial Neoplasms
2
Endometrial Hyperplasia
2
Carcinoma, Intraductal, Noninfiltrating
2
Urothelial Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Prostatic Neoplasms
1
Prediabetic State
1
Pancreatic Adenocarcinoma
1
Mouth Neoplasms
1
Monoclonal Gammopathy of Undetermined Significance
1
Metabolic Diseases
1
Lung Neoplasms
1
Infertility
1
Hyperplasia
1
Diabetes Mellitus
1
Breast Neoplasms
1
Breast Carcinoma In Situ
1
Advanced Solid Malignancies
1
Advanced Pancreatic Cancer
1
Interventions
enzalutamide
33
Abiraterone Acetate
28
apalutamide
25
Radiotherapy
25
Prednisone
25
Magnetic Resonance Spectroscopy
25
Androgen Antagonists
24
Leuprolide
21
Radiosurgery
19
darolutamide
18
Docetaxel
17
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Gonadotropin-Releasing Hormone
14
gallium 68 PSMA-11
12
Specimen Handling
12
Goserelin
12
pembrolizumab
11
Radiotherapy, Intensity-Modulated
11
Radiation
11
bicalutamide
10
abiraterone
10
Pluvicto
10
Carboplatin
9
Brachytherapy
9
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
9
relugolix
8
luprolide acetate gel depot
8
Standard of Care
8
Nivolumab
8
olaparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Prostatic Neoplasms
×
Metformin
×
Clear all
NCT00268476
2023-04-18
STAMPEDE
Medical Research Council
Phase 2/3
Active not recruiting
11,992 enrolled